SeekingAlpha · Aug 6, 2026
Hikma Pharmaceuticals PLC 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2026 Q2 earnings call.
HK
NASDAQ · HKMPY
Hikma Pharmaceuticals PLC
Healthcare · Drug Manufacturers - Specialty & Generic
$44.60
Down-$0.76 (-1.66%)
Updated Aug 18, 2026, 8:38 PM
SID Score
5.9/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 4.58B
- P/E ratio
- 12.27
- Dividend yield
- 3.77%
- 52-week range
- — – —
- Volume
- 349
- Avg. volume
- 4.42K
Price performance
HKMPY price history
1M range · 0 trading sessions · Daily adjusted prices
HKMPY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest HKMPY news
The latest Smart Investors Daily articles mentioning HKMPY.
Stock researchCompany · Overview
HKMPY research
Overview
Company profile and research snapshot.
Company profile
HIKMA PHARMS PLC S/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 16, 2026 | Citigroup | Buy | — |
| Jun 22, 2026 | Deutsche | Buy | — |
| May 5, 2026 | Jefferies | Buy | — |
| Apr 28, 2026 | Berenberg Bank | Buy | — |
| Mar 4, 2026 | Berenberg Bank | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call August 6, 2026 4:30 AM EDTCompany ParticipantsGuy Featherstone - Associate Director of Investor...
SeekingAlpha · Aug 6, 2026
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call Prepared Remarks Transcript
Hikma Pharmaceuticals PLC (HKMPY) Q2 2026 Earnings Call August 5, 2026 8:00 PM EDTCompany ParticipantsPresentationUnknown AttendeeHello, everyone.
SeekingAlpha · Jun 8, 2026
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Emergent BioSolutions remains under significant pressure, with persistent revenue, margin, and earnings declines. Learn more about EBS stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
